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ABSTRACT
Patients with hemophilia generally have a reduced frequency of coronary artery disease compared to the general population. 
As advances in the management of hemophilia have increased their life expectancy, the prevalence of coronary artery dis-
ease also has increased. However, there are no standard treatment guidelines for coronary artery disease in patients with he-
mophilia, especially in the field of coronary intervention. We report the case of a patient with severe hemophilia A who pre-
sented with acute coronary syndrome and was successfully treated with percutaneous coronary intervention. (Korean Circ J 
2010;40:527-529)
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Introduction
Acute coronary syndrome is rare in patients with hemo-
philia, potentially due to shorter lifespan or perhaps because 
of coagulation factor VIII abnormality.
1) Hemophilia A di-
rectly protects against the development of coronary artery dis-
ease.
2)3) However, patients with hemophilia might not be pro-
tected against atherosclerosis, as demonstrated by clinical 
studies
4) and autopsy reports on hemophiliacs with fatal myo-
cardial infarction showing extensive atherosclerotic lesions, 
but only rarely fresh thrombi.
5) Girolami et al.
5) studied 36 cas-
es of acute coronary syndrome in patients with hemophilia A. 
In most cases, the event occurred during or after the infusion 
of recombinant factor VIII concentrates, desmopressin (DD-
AVP), and prothrombin complex concentrates. 
The treatment of choice in patients with acute coronary syn-
drome is primary coronary angioplasty with stent implanta-
tion, although invasive treatment carries the risk of hemor-
rhagic adverse events. We report a case of hemophilia A with 
acute coronary syndrome, not precipitated by anticoagulation 
therapy, who was successfully treated by percutaneous trans-
luminal coronary angioplasty with stent implantation.
Case
A 52-year-old male patient presented to the emergency de-
partment with intermittent chest pain at rest. The patient had 
no cardiovascular risk factors except for a 20 pack-year his-
tory of smoking. The patient had severe hemophilia A diag-
nosed at 10 years of age. The patient reported that he had re-
ceived coagulation factor VIII on occasion because of bleed-
ing into the knee joints. Physical examination revealed a body 
temperature of 36.6°C, blood pressure 110/70 mmHg, pulse 
rate 70/minute, and respiration rate 20/minute.
The electrocardiogram (ECG) showed T-wave inversions in 
precordial leads V1 to V6 and slight elevation of the ST segment 
in precordial leads V1 and V2. The MB fraction of creatine kinase 
was 2.1 ng/ mL (normal, <5.0 ng/mL) and troponin-I was 0.194 
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ng/mL (normal, <0.5 ng/mL). Factor VIII activity was less than 
1% (normal, 60-140%) and factor VIII inhibitor antibodies were 
0.26 (normal, <0.01). Echocardiography showed regional wall 
motion abnormalities at the anterior and septal wall of the 
apex and preserved left ventricular systolic function with a 
51.8% ejection fraction. 
Chest pain decreased during infusion of isosorbide dinitra-
te, and the patient was admitted to the coronary care unit. Af-
ter admission, a coronary CT scan was performed and show-
ed significant narrowing in the proximal left anterior des-
cending artery (LAD). Angina recurred one day later, even with 
optimal medical treatment. Therefore, the patient was pre-
pared for coronary angiography (CAG) and angioplasty.
Following the advice of a hematologist, the patient received 
2,500 IU of monoclonal coagulation factor VIII (Greenmono
®, 
Baxter, Deerfield, IL, USA) prior to the procedure in addition 
to 1,500 IU of factor VIII at 12, 24, and 48 hours after the proce-
dure. Catheterization was performed via the right femoral ar-
tery (Judkins technique). The patient received 70 IU/kg of un-
fractionated heparin and a loading dose of clopidogrel (300 
mg). CAG revealed an 80% stenosis of the proximal segment 
and 40% in the mid segment of the LAD, some non-stenotic 
changes in the left circumflex, and a diminished right coro-
nary artery (Fig. 1A). Balloon angioplasty was performed at the 
proximal LAD. However, the outcome was suboptimal and a 
cobalt-chromium coronary stent 3.5×18 mm (Vision
®, Abbott 
Inc, Santa Clara, CA, USA) was implanted (Fig. 1B). To stop 
bleeding at the puncture site, we compressed the site manual-
ly for about 30 minutes. No local complications were observed 
and the patient did not complain of chest pain. The patient 
was discharged on aspirin 100 mg/d and clopidogrel 75 mg/
d for 1 month, followed by long-term aspirin therapy 100 
mg/d and regular coagulation factor VIII supplements.
Ten months after the initial procedure, the patient was ad-
mitted to perform a follow-up CAG for evaluation of the pa-
tency of the implanted stent. The patient had taken aspirin, an 
angiotensin receptor blocker, nicorandil, and a calcium chan-
nel blocker, and also had received regular coagulation factor 
VIII supplements. He did not report any chest pain or any 
hemorrhagic complications. The echocardiography showed a 
normal ejection fraction (63.8%) without regional wall motion 
abnormalities. However, the CAG revealed 50% tubular con-
centric luminal narrowing of the proximal segment of the 
LAD stent (Fig. 2). The patient refused further evaluations and 
invasive treatment. Medical therapy has continued and the 
patient has remained asymptomatic.
Discussion
The diagnosis of severe hemophilia in a patient with acute 
coronary syndrome should not delay invasive procedures and 
optimal medical therapy. The primary goal is to intervene be-
fore a full myocardial infarction. Anti-thrombotic treatment, 
particularly with percutaneous coronary intervention (PCI) 
and stent implantation, poses a therapeutic dilemma in pa-
tients with impaired coagulation. PCI requires the use of an-
ticoagulants in patients with hemophilia, which can increase 
the risk of local complications.
Substituting the missing coagulation factor can reduce the 
bleeding risk during the procedure, even though it may in-
crease the risk of acute thrombosis in a patient with unstable 
atherosclerotic plaques. According to the World Federation 
of Hemophilia recommendations, patients with hemophilia 
A that are going to undergo major surgery should be supple-
mented with factor VIII before the procedure to achieve the 
level of 80-100% of factor VIII activity. However, there is no 
similar protocol for coagulation supplementation prior to 
PCI.
Anticoagulation therapy is important to avoid thrombosis 
both from procedure-related complications and from further 
Fig. 1. Initial coronary angiography. Coronary angiography reveals focal luminal narrowing at the proximal and mid segments of the left ante-
rior descending artery (A). Bare-metal stent (Vision
®, Abbott Inc, Santa Clara, CA, USA) was successfully implanted at the proximal lesion (B). 
A   B  Dong-Kie Kim, et al.   529
progression of coronary luminal narrowing; heparin is usually 
titrated to an optimal activated clotting time.
6) Bivalirudin 
does not require monitoring and has a low rate of bleeding 
complications because it inhibits circulating and clot-bound 
thrombin directly, unlike heparin.
7)8)
Antiplatelet therapies are as important as anticoagulation 
therapy for the prevention of acute thrombosis in an implant-
ed stent;
9) hemophilia is not associated with abnormalities of 
platelet number or platelet function. Current guidelines reco-
mmend dual antiplatelet therapy with aspirin and clopido-
grel for at least 1 month for bare-metal stents and for at least 
1 year for drug-eluting stents.
10) However, antiplatelet therapy 
can increase the hemorrhagic tendency in these patients. 
Even with disturbed coagulation, antiplatelet therapy is im-
portant for hemophiliacs with PCI to prevent stent thrombo-
sis. Bovenzi et al.
11) reported a case of acute stent thrombosis 
in a patient with hemophilia B after coronary stent implanta-
tion who was not treated with aspirin or clopidogrel.
In our case, we used a bare-metal stent for early withdraw-
al of antiplatelet therapy. Aspirin as secondary prophylaxis 
against ischemic coronary events has been reported in patients 
with mild and moderate hemophilia.
12) Here, long-term aspi-
rin did not increase the incidence of hemorrhagic events, 
probably due to regular substitution of coagulation factor 
VIII. When long-term aspirin is needed in patients with se-
vere hemophilia, Ferrario et al.
13) suggested that coagulation 
factor VIII replacement should be prescribed also. Bare metal 
stents do not prevent neointimal hyperplasia. There are no re-
ports on the use of drug-eluting stent implantation in patients 
with hemophilia; however, with concerns about bleeding dia-
thesis, bare-metal stents are regarded as safe.
In conclusion, a PCI in a patient with severe hemophilia 
and acute coronary syndrome has acceptable complication 
risks. Antiplatelet therapy is important for preventing throm-
bus formation in the implanted stent even in patients with   
abnormal coagulation.
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Fig. 2. Follow-up coronary angiography 10 months after the initial 
procedure. Coronary angiography showed 70% in-stent restenosis 
at the proximal left anterior descending artery (arrows). However, the 
patient was asymptomatic but managed with medical therapy.